Heterologous Booster Immunization Based on Inactivated SARS-CoV-2 Vaccine Enhances Humoral Immunity and Promotes BCR Repertoire Development

Overview

Journal Vaccines (Basel)

Date 2024 Feb 24

PMID 38400104

Authors

Xinghang Li

Fengyuan Zeng

Rong Yue

Danjing Ma

Ziyan Meng

Qi Li

Zhenxiao Zhang

Haobo Zhang

Yuansheng Liao

Yun Liao

Guorun Jiang

Heng Zhao

Li Yu

Dandan Li

Ying Zhang

Longding Liu

Qihan Li

Affiliations

Soon will be listed here.

Abstract

Recent studies have indicated that sequentially administering SARS-CoV-2 vaccines can result in increased antibody and cellular immune responses. In this study, we compared homologous and heterologous immunization strategies following two doses of inactivated vaccines in a mouse model. Our research demonstrates that heterologous sequential immunization resulted in more immune responses displayed in the lymph node germinal center, which induced a greater number of antibody-secreting cells (ASCs), resulting in enhanced humoral and cellular immune responses and increased cross-protection against five variant strains. In further single B-cell analysis, the above findings were supported by the presence of unique B-cell receptor (BCR) repertoires and diversity in CDR3 sequence profiles elicited by a heterologous booster immunization strategy.

Citing Articles

Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency.

Song Y, Wang J, Yang Z, He Q, Bao C, Xie Y Front Immunol. 2024; 15:1406138.

PMID: 38975334 PMC: 11224535. DOI: 10.3389/fimmu.2024.1406138.

References

He Q, Mao Q, An C, Zhang J, Gao F, Bian L . Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021; 10(1):629-637. PMC: 8009122. DOI: 10.1080/22221751.2021.1902245. View

Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton P . Vaccines for COVID-19: Where do we stand in 2021?. Paediatr Respir Rev. 2021; 39:22-31. PMC: 8274273. DOI: 10.1016/j.prrv.2021.07.001. View

Chiu N, Chi H, Tu Y, Huang Y, Tai Y, Weng S . To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev Vaccines. 2021; 20(10):1211-1220. PMC: 8425437. DOI: 10.1080/14760584.2021.1971522. View

Li J, Hou L, Guo X, Jin P, Wu S, Zhu J . Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022; 28(2):401-409. PMC: 8863573. DOI: 10.1038/s41591-021-01677-z. View

Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C . Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med. 2021; 386(5):492-494. PMC: 8823651. DOI: 10.1056/NEJMc2119358. View

Zhang Y, Yang Y, Qiao N, Wang X, Ding L, Zhu X . Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults. Front Med. 2022; 16(1):93-101. PMC: 8815383. DOI: 10.1007/s11684-021-0914-x. View

Kak G, Raza M, Tiwari B . Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018; 9(1):64-79. DOI: 10.1515/bmc-2018-0007. View

Mesin L, Ersching J, Victora G . Germinal Center B Cell Dynamics. Immunity. 2016; 45(3):471-482. PMC: 5123673. DOI: 10.1016/j.immuni.2016.09.001. View

Mintz M, Cyster J . T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev. 2020; 296(1):48-61. PMC: 7817257. DOI: 10.1111/imr.12860. View

10.

Duarte-Salles T, Prieto-Alhambra D . Heterologous vaccine regimens against COVID-19. Lancet. 2021; 398(10295):94-95. PMC: 8233006. DOI: 10.1016/S0140-6736(21)01442-2. View

11.

Jackson C, Farzan M, Chen B, Choe H . Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2021; 23(1):3-20. PMC: 8491763. DOI: 10.1038/s41580-021-00418-x. View

12.

Wang C, Hwang K, Kuo H, Peng W, Shen Y, Kuo B . A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022; 132(10). PMC: 9106357. DOI: 10.1172/JCI157707. View

13.

Limami Y, Khalki L, Zaid N, Khyatti M, Turk J, Ammara M . Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation. Semin Thromb Hemost. 2021; 48(1):109-111. DOI: 10.1055/s-0041-1728831. View

14.

Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J . Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022; 607(7917):128-134. PMC: 9259484. DOI: 10.1038/s41586-022-04778-y. View

15.

Gao H, Yu L, Yan F, Zheng Y, Huang H, Zhuang X . Landscape of B Cell Receptor Repertoires in COVID-19 Patients Revealed Through CDR3 Sequencing of Immunoglobulin Heavy and Light Chains. Immunol Invest. 2022; 51(7):1994-2008. DOI: 10.1080/08820139.2022.2092407. View

16.

Patone M, Mei X, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M . Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021; 28(2):410-422. PMC: 8863574. DOI: 10.1038/s41591-021-01630-0. View

17.

Cao H, Yang S, Wang Y, Luan N, Yin X, Lin K . An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines (Basel). 2021; 9(11). PMC: 8617830. DOI: 10.3390/vaccines9111261. View

18.

Laidlaw B, Ellebedy A . The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. 2021; 22(1):7-18. PMC: 8647067. DOI: 10.1038/s41577-021-00657-1. View

19.

Buckner C, Kardava L, El Merhebi O, Narpala S, Serebryannyy L, Lin B . Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. Cell. 2022; 185(23):4333-4346.e14. PMC: 9513331. DOI: 10.1016/j.cell.2022.09.032. View

20.

Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S . Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med. 2021; 29(3). PMC: 8754745. DOI: 10.1093/jtm/taab191. View